CS
CLGN icon

Credit Suisse’s CollPlant Biotechnologies CLGN Stock Holding History

Credit Suisse’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,100
Closed -$50.9K – 3345
2022
Q4 		$50.9K Buy
+6,100
New +$41.7K ﹤0.01% 3405

Other funds holding CLGN

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse's CLGN Position: Q1 2023 in Review

Credit Suisse sold out of CollPlant Biotechnologies (CLGN) in Q1 2023, closing a stake of 6,100 shares — an estimated $50.9K sold.

Credit Suisse first reported a position in CLGN in Q4 2022 and held it in 1 quarter. The position peaked at $50.9K in Q4 2022. 18 funds tracked by Wall St. Rank hold CLGN as of Q1 2023.

  • Credit Suisse reported no remaining CollPlant Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 6,100 CollPlant Biotechnologies shares in Q1 2023, an estimated $50.9K.
  • Credit Suisse first reported a position in CollPlant Biotechnologies in Q4 2022 and held it in 1 quarter.
  • Credit Suisse's CollPlant Biotechnologies position peaked at $50.9K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.